KR20100090726A - 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 - Google Patents

수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 Download PDF

Info

Publication number
KR20100090726A
KR20100090726A KR1020107016079A KR20107016079A KR20100090726A KR 20100090726 A KR20100090726 A KR 20100090726A KR 1020107016079 A KR1020107016079 A KR 1020107016079A KR 20107016079 A KR20107016079 A KR 20107016079A KR 20100090726 A KR20100090726 A KR 20100090726A
Authority
KR
South Korea
Prior art keywords
formulation
soluble cellulose
water soluble
weight
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107016079A
Other languages
English (en)
Korean (ko)
Inventor
폴 리챠드 겔레트
마이클 데비스 파커
마터스 마르셀 드
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20100090726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20100090726A publication Critical patent/KR20100090726A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107016079A 2002-02-26 2003-02-24 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 Ceased KR20100090726A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0204392.5 2002-02-26
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462.6 2002-05-30
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition
GB0213267.8 2002-06-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020047013177A Division KR101002374B1 (ko) 2002-02-26 2003-02-24 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물

Publications (1)

Publication Number Publication Date
KR20100090726A true KR20100090726A (ko) 2010-08-16

Family

ID=27767732

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107016079A Ceased KR20100090726A (ko) 2002-02-26 2003-02-24 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
KR1020047013177A Expired - Lifetime KR101002374B1 (ko) 2002-02-26 2003-02-24 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020047013177A Expired - Lifetime KR101002374B1 (ko) 2002-02-26 2003-02-24 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물

Country Status (29)

Country Link
US (2) US20050163835A1 (enExample)
EP (1) EP1480679B1 (enExample)
JP (1) JP4544863B2 (enExample)
KR (2) KR20100090726A (enExample)
CN (1) CN1326569C (enExample)
AR (1) AR038848A1 (enExample)
AT (1) ATE362771T1 (enExample)
AU (1) AU2003208444B2 (enExample)
BR (1) BRPI0307786B8 (enExample)
CA (1) CA2476587C (enExample)
CO (1) CO5601038A2 (enExample)
CY (1) CY1108026T1 (enExample)
DE (1) DE60313956T2 (enExample)
DK (1) DK1480679T3 (enExample)
ES (1) ES2286406T3 (enExample)
IL (2) IL163642A0 (enExample)
IS (1) IS2462B (enExample)
MX (1) MXPA04008307A (enExample)
MY (1) MY135609A (enExample)
NO (1) NO328658B1 (enExample)
NZ (1) NZ534513A (enExample)
PL (1) PL208114B1 (enExample)
PT (1) PT1480679E (enExample)
RU (1) RU2318518C2 (enExample)
SA (1) SA03240043B1 (enExample)
TW (1) TWI271193B (enExample)
UA (1) UA76325C2 (enExample)
UY (1) UY27682A1 (enExample)
WO (1) WO2003072139A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003212500B2 (en) 2002-02-26 2008-01-03 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
KR101313395B1 (ko) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물
MX2009004434A (es) 2006-10-27 2009-05-08 Pfizer Prod Inc Capsulas duras de hidroxipropilmetilcelulosa y procedimiento de fabricacion.
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
KR20120046216A (ko) * 2009-07-02 2012-05-09 와이어쓰 엘엘씨 3-시아노퀴놀린 정제 제형 및 이의 용도
CN102655858B (zh) * 2009-12-22 2015-11-25 Abbvie公司 Abt-263胶囊
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
MY165884A (en) 2010-11-23 2018-05-18 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
RS58703B1 (sr) 2012-09-28 2019-06-28 Takeda Pharmaceuticals Co Metoda proizvodnje derivata tienopirimidina
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
WO2016096999A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising gefifinib
JP6730978B2 (ja) * 2015-02-26 2020-07-29 武田薬品工業株式会社 固形製剤
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
WO2018060463A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
EP0716597A1 (en) * 1993-08-30 1996-06-19 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
WO1998038984A2 (en) * 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
AU2003212500B2 (en) * 2002-02-26 2008-01-03 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
UY27682A1 (es) 2003-10-31
US20090186890A1 (en) 2009-07-23
MXPA04008307A (es) 2004-11-26
PL208114B1 (pl) 2011-03-31
IS2462B (is) 2008-11-15
TW200304379A (en) 2003-10-01
EP1480679B1 (en) 2007-05-23
TWI271193B (en) 2007-01-21
MY135609A (en) 2008-05-30
BRPI0307786B1 (pt) 2018-03-13
DE60313956D1 (de) 2007-07-05
DK1480679T3 (da) 2007-09-03
CN1326569C (zh) 2007-07-18
NO20043866L (no) 2004-09-15
AU2003208444A1 (en) 2003-09-09
CA2476587A1 (en) 2003-09-04
KR20040088524A (ko) 2004-10-16
PL372215A1 (en) 2005-07-11
BRPI0307786B8 (pt) 2021-05-25
EP1480679A1 (en) 2004-12-01
KR101002374B1 (ko) 2010-12-17
ATE362771T1 (de) 2007-06-15
JP4544863B2 (ja) 2010-09-15
IL163642A (en) 2007-07-24
US20050163835A1 (en) 2005-07-28
SA03240043B1 (ar) 2007-05-06
UA76325C2 (uk) 2006-07-17
RU2318518C2 (ru) 2008-03-10
IL163642A0 (en) 2005-12-18
CO5601038A2 (es) 2006-01-31
CN1638805A (zh) 2005-07-13
CY1108026T1 (el) 2013-09-04
NZ534513A (en) 2007-04-27
BR0307786A (pt) 2004-12-07
PT1480679E (pt) 2007-07-18
IS7420A (is) 2004-08-24
AR038848A1 (es) 2005-01-26
ES2286406T3 (es) 2007-12-01
AU2003208444B2 (en) 2006-10-26
CA2476587C (en) 2010-05-04
JP2005523293A (ja) 2005-08-04
RU2004129280A (ru) 2005-06-10
DE60313956T2 (de) 2008-05-15
HK1070585A1 (en) 2005-06-24
WO2003072139A1 (en) 2003-09-04
NO328658B1 (no) 2010-04-19

Similar Documents

Publication Publication Date Title
KR101002374B1 (ko) 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
US20250017930A1 (en) Pharmaceutical compositions comprising azd9291
JPWO2011136376A1 (ja) 腸溶性錠剤
US20070141141A1 (en) Pharmaceutical composition
ZA200406361B (en) Pharmaceutical formulation of iressa comprising a watersoluble cellulose derivative.
KR102389339B1 (ko) 방출 제어되는 고함량 탐스로신 정제 조성물 및 이의 제조방법
HK1070585B (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
HK40073463B (en) Therapeutic for gout or hyperuricemia
HK40047687B (en) Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof
HK1228245B (en) Pharmaceutical compositions comprising azd9291

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20100719

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100823

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100823

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I